US2010029741A1PendingUtilityA1

Fused heterocycles

64
Assignee: SEPRACOR INCPriority: Jun 30, 2006Filed: Aug 7, 2009Published: Feb 4, 2010
Est. expiryJun 30, 2026(expired)· nominal 20-yr term from priority
Inventors:James M. DorseyMichele L. R. HeffernanQun Kevin FangRobert J. FoglesongSeth Cabot HopkinsCyprian O. OgbuMustapha SoukriKerry L. Spear
A61P 43/00A61P 25/08C07D 491/04A61P 25/00A61P 25/24C07D 495/04A61K 31/407A61P 25/16A61P 25/18A61P 29/00A61P 25/04A61P 25/28
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention provides methods of improving cognitive function by administering to a subject a therapeutically effective amount of a fused heterocycle having the formula: in which R 1 is a member selected from the group consisting of H, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R 2 is a member selected from the group consisting of H substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R 3 is a member selected from the group consisting of H, C 1 -C 6 substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R 4 is a member selected from OH and O − X + , in which X + is positive ion which is a member selected from organic positive ions and inorganic positive ions. Substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl moieties have the formula: in which Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. The index n is an integer from 1 to 4.

Claims

exact text as granted — not AI-modified
1 . A method of treating a subject for a condition selected from loss of memory, loss of cognition and a combination thereof, said method comprising administering to said subject a therapeutically effective amount of a D-amino oxidase inhibitor having the formula: 
     
       
         
         
             
             
         
       
     
     in which
 R 1  is a member selected from the group consisting of H, and substituted or unsubstituted arylalkyl; 
 R 2  is a member selected from the group consisting of H, and substituted or unsubstituted arylalkyl; and 
 R 4  is a member selected from OH and O − X +   
 wherein
 X +  is a positive ion which is a member selected from organic positive ions and inorganic positive ions, 
 
 wherein
 substituted or unsubstituted arylalkyl has the formula: 
 
 
     
       
         
         
             
             
         
       
       
         in which
 Ar is substituted or unsubstituted aryl; and 
 n is an integer from 1 to 4. 
 
       
     
   
   
       2 . The method according to  claim 1  wherein said condition is a result of Alzheimer's disease. 
   
   
       3 . The method according to  claim 1  wherein said condition is a result of schizophrenia. 
   
   
       4 . The method according to  claim 1  wherein said D-amino oxidase inhibitor is administered to said subject as a pharmaceutical composition in unit dosage form comprising, per dosage unit, a pharmaceutically acceptable carrier and a daily dosage of said D-amino oxidase inhibitor in an amount of about 0.1 mg to about 7000 mg. 
   
   
       5 . The method according to  claim 4  wherein said D-amino oxidase inhibitor is present in said pharmaceutical composition in an amount of about 50 mg to about 500 mg. 
   
   
       6 . The method according to  claim 5  wherein said D-amino oxidase inhibitor is present in said pharmaceutical composition in an amount of about 1 mg to about 100 mg. 
   
   
       7 . The method according to  claim 6  wherein said D-amino oxidase inhibitor is present in said pharmaceutical composition in an amount of about 25 mg to about 50 mg. 
   
   
       8 . The method according to  claim 4  wherein said unit dosage is an oral dosage form. 
   
   
       9 . The method according to  claim 6  wherein oral dosage form is a member selected from a tablet and a capsule. 
   
   
       10 . A method of treating a subject for a condition selected from loss of memory, loss of cognition and a combination thereof, said method comprising administering to said subject a therapeutically effective amount of a D-amino oxidase inhibitor as a pharmaceutical composition comprising, in single or divided doses, a pharmaceutically acceptable carrier and a daily dosage from about 0.1 mg to about 7000 mg of said D-amino oxidase inhibitor, said D-amino oxidase inhibitor having the formula: 
     
       
         
         
             
             
         
       
     
     in which
 R 1  is a member selected from the group consisting of H, and substituted or unsubstituted arylalkyl; 
 R 2  is a member selected from the group consisting of H, and substituted or unsubstituted arylalkyl; and 
 R 4  is a member selected from OH and O − X +   
 wherein
 X +  is a positive ion which is a member selected from organic positive ions and inorganic positive ions, 
 
 wherein
 substituted or unsubstituted arylalkyl has the formula: 
 
 
     
       
         
         
             
             
         
       
       
         in which
 Ar is substituted or unsubstituted aryl; and 
 n is an integer from 1 to 4. 
 
       
     
   
   
       11 . The method according to  claim 10  wherein said condition is a result of Alzheimer's disease. 
   
   
       12 . The method according to  claim 11  wherein said condition is a result of schizophrenia. 
   
   
       13 . The method according to  claim 10  wherein said D-amino oxidase inhibitor is present in said pharmaceutical composition in an amount of about 50 mg to about 500 mg. 
   
   
       14 . The method according to  claim 13  wherein said D-amino oxidase inhibitor is present in said pharmaceutical composition in an amount of about 1 mg to about 100 mg. 
   
   
       15 . The method according to  claim 14  wherein said D-amino oxidase inhibitor is present in said pharmaceutical composition in an amount of about 25 mg to about 50 mg. 
   
   
       16 . The method according to  claim 10  wherein said unit dosage is an oral dosage form. 
   
   
       17 . The method according to  claim 16  wherein oral dosage form is a member selected from a tablet and a capsule. 
   
   
       18 . A method of  claim 1   wherein
 R 1  is H; 
 R 2  is H; and 
 R 4  is a member selected from OH and O − X +   
 wherein
 X +  is a positive ion which is a member selected from organic positive ions and inorganic positive ions. 
 
   
   
   
       19 . The method according to  claim 18  wherein said condition is a result of Alzheimer's disease. 
   
   
       20 . The method according to  claim 18  wherein said condition is a result of schizophrenia.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.